Home > Resources > Whitepapers > ON CANCER-ASSOCIATED CACHEXIA

ON CANCER-ASSOCIATED CACHEXIA

Malignant tumors have the ability to induce a chronic and systemic inflammatory environment that gives rise to cachexia. Metastatic disease can in fact be potently active at inducing cachexia, with onset occurring in the presence of remarkably little overall tumor burden. The efficient induction of cachexia can be explained by the fact that during metastasis, hematogenous tumor cells have the opportunity to closely interact with—and activate—leukocytes. Systemic distribution of these activated inflammatory leukocytes are a source of chronic inflammation. Specifically, these inflammatory nuclei relay “danger” signals to the central nervous system (CNS) by way of the hypothalamus.

Spotlight

GNF

The Genomics Institute of the Novartis Research Foundation (GNF), founded in 1999 and now with over 560 employees, is under the umbrella of the Novartis Institute for Biomedical Research (NIBR) and is affiliated with the Novartis Institute for Developing World Medical Research (NIDWMR). GNF applies integrated state-of-the-art technologies in chemistry, biology, automation, and information sciences in order to pursue new approaches towards the understanding of complex biomedical problems in cancer biology, immunology, neuroscience, and metabolic as well as infectious disease.

OTHER WHITEPAPERS

Eliminate Noisy Oxygen Measurements in Bioreactors

whitePaper | March 27, 2023

Controlling the dissolved oxygen level in fermentation vessels and bioreactors is vital to maximizing production yield and ensuring high end-product quality.

The EU Clinical Trials Regulation − What You Need to Know

whitePaper | March 22, 2022

The Clinical Trials Regulation has retained some definitions and refined others. For example the definition of “clinical study”: “Any investigation in relation to humans intended: (a) to discover or verify the clinical, pharmacological or other pharmacodynamic.

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.